ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1527

Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program

Holly Glover 1, Kristine Kucera 2, Alan Mendelsohn3, Jeff Parno 3, Stephen Rozzo 3, Frank Ferritto 4 and Renata Block 5, 1Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, 2North Texas Dermatology, Richardson, TX, USA, Richardson, TX, 3Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 4Polley Dermatology, Wilson, NC, USA, Wilson, NC, 5Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: clinical trials and laboratory tests, interleukins (IL), monoclonal antibodies, psoriasis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731]) and 2 phase 3 clinical studies (reSURFACE 1 [NCT01722331] and 2 [NCT01729754]).1,2 We evaluated hematological laboratory findings for evidence of drug-induced changes following TIL treatment using data from 3 randomized, placebo-controlled trials.

Methods: Data were pooled from the P05495 and reSURFACE 1 and 2 trials of patients with moderate to severe chronic plaque psoriasis. Here we report changes at week 52 vs baseline in hematological parameters for patients with continuous exposure to TIL 100 mg or 200 mg administered at week 0 and week 4, and every 12 weeks thereafter up to week 52 (P05495 and reSURFACE 2) or week 64 (reSURFACE 1). An analysis of changes in hematological parameters from baseline to worst values obtained relative to reference ranges is also reported.

Results: Among patients with continuous exposure to TIL 100 mg and 200 mg, limited changes in hematological parameters were observed. Mean (standard deviation) changes at week 52 vs baseline for TIL 100 mg (N = 249 patients with data) were 0.3% (2.4) for hematocrit, 0.1 g/dL (0.7) for hemoglobin, −4.0 x 103/µL (37.0 x 103) for platelets, 0.1 x 103/µL (0.4 x 103) for lymphocytes, 0 x 106/µL (0.3 x 106) for erythrocytes, and −0.5 x 103/µL (1.6 x 103) for neutrophils. Corresponding values for TIL 200 mg (N = 204 patients with data) were 0.3% (2.4) for hematocrit, 0.1 g/dL (0.8) for hemoglobin, −6.8 x 103/µL (36.9 x 103) for platelets, 0 x 103/µL (0.5 x 103) for lymphocytes, 0 x 106/µL (0.2 x 106) for erythrocytes, and −0.4 x 103/µL (1.9 x 103) for neutrophils. Similarly, limited changes were also seen for leukocytes, monocytes, eosinophils, lymphocytes/leukocytes, eosinophils/leukocytes, and basophils/leukocytes. The majority of patients (80.1%–100%) had hematological parameter values within normal ranges at baseline; worst values for most of these patients remained within normal ranges over 52 weeks. No changes correlated with adverse events such as infections or thrombocytopenia.

Conclusion: In this pooled analysis of phase 2b and phase 3 trials, only limited changes in hematological parameters—including white blood cells, erythrocytes, and platelets—were observed in patients treated with TIL over 52 weeks. Based on these data, patients receiving TIL are unlikely to require routine laboratory testing for hematological parameters.

Medical writing support was provided by Judy Phillips, DVM, PhD, of AlphaBioCom, LLC.

References:

1. Papp K, et al. Br J Dermatol. 2015;173:930−939.
2. Reich K, et al. Lancet. 2017;390:276–288.


Disclosure: H. Glover, Pfizer, 5, 8, Galderma, 5, 8, Aqua, 5, 8, Ortho Dermatologics, 5, 8; K. Kucera, AbbVie, 5, 8, Novartis, 5, 8, Ortho Dermatologics, 5, 8, Pfizer, 5, 8, Encore, 5, 8, Sun Pharmaceutical Industries, Inc, 5, 8; A. Mendelsohn, Johnson and Johnson, 1, 4, Sun Pharmaceutical Industries, Inc, 3, Sun Pharmaceutical Industries, Inc., 3; J. Parno, Kyowa Kirin Pharmaceutical Development, Inc, 9, Kyowa Kirin Pharmaceutical Development, Inc., 9, Sun Pharmaceutical Industries, Inc, 3, 9; S. Rozzo, Sun Pharmaceutical Indsutries, Inc, 3, Sun Pharmaceutical Industries, Inc, 3, Sun Pharmaceutical Industries, Inc., 3; F. Ferritto, Promius, 5, 8, EPI, 5, 8, AbbVie, 5, 8, Encore, 5, 8; R. Block, Ortho Dermatologics, 8, Cutanea, 8, Medimetriks, 4.

To cite this abstract in AMA style:

Glover H, Kucera K, Mendelsohn A, Parno J, Rozzo S, Ferritto F, Block R. Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/limited-changes-in-hematological-parameters-during-tildrakizumab-treatment-post-hoc-analysis-of-data-from-the-tildrakizumab-psoriasis-clinical-program/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/limited-changes-in-hematological-parameters-during-tildrakizumab-treatment-post-hoc-analysis-of-data-from-the-tildrakizumab-psoriasis-clinical-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology